This grant from the National Institute of Mental Health aims to advance translational research focused on mood and psychotic disorders during the menopause transition (MT). Its purpose is to better understand the emergence and worsening of conditions like perimenopausal depression, anxiety, bipolar disorder, and schizophrenia to identify targets for novel treatment interventions. The funding encourages innovative research into the underlying neurobiological and behavioral mechanisms. It seeks interdisciplinary collaboration, investigating aspects such as classic depressive symptoms combined with menopause symptoms, the role of reproductive steroids, diagnosis at menopausal stage, co-occurring psychiatric and menopause symptoms, and psychosocial factors. Proposals should present comprehensive neurobiological and mechanistic hypothesis-driven work.
Opportunity ID: 335876
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-22-035 |
| Funding Opportunity Title: | Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.242 — Mental Health Research Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Sep 21, 2021 |
| Last Updated Date: | Jan 06, 2023 |
| Original Closing Date for Applications: | Jan 07, 2025 |
| Current Closing Date for Applications: | Jan 07, 2023 |
| Archive Date: | Feb 06, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal governments (Federally recognized) Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Small businesses City or township governments Independent school districts County governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
Reissue of RFA-MH-21-105 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-22-035.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| expired and re-issued as PAR-23-097 | Jan 06, 2023 | |
| Sep 21, 2021 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-22-035 |
| Funding Opportunity Title: | Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.242 — Mental Health Research Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Sep 21, 2021 |
| Last Updated Date: | Jan 06, 2023 |
| Original Closing Date for Applications: | Jan 07, 2025 |
| Current Closing Date for Applications: | Jan 07, 2023 |
| Archive Date: | Feb 06, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal governments (Federally recognized) Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Small businesses City or township governments Independent school districts County governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
Reissue of RFA-MH-21-105 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-22-035.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-22-035 |
| Funding Opportunity Title: | Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.242 — Mental Health Research Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 21, 2021 |
| Last Updated Date: | Sep 21, 2021 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jan 07, 2025 |
| Archive Date: | Feb 12, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses State governments County governments Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Special district governments Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Reissue of RFA-MH-21-105 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-22-035.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Related Documents
Folder 335876 Full Announcement-PAR-22-035 -> PAR-22-035-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00269816 | Jan 05, 2022 | Jan 07, 2023 | View | |
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00269071 | Jan 05, 2022 | Jan 24, 2022 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277788 | Nov 01, 2022 | Jan 07, 2023 | View |
Package 1
Mandatory forms
335876 RR_SF424_5_0-5.0.pdf
335876 PHS398_CoverPageSupplement_5_0-5.0.pdf
335876 RR_OtherProjectInfo_1_4-1.4.pdf
335876 PerformanceSite_4_0-4.0.pdf
335876 RR_KeyPersonExpanded_4_0-4.0.pdf
335876 PHS398_ResearchPlan_4_0-4.0.pdf
335876 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335876 RR_Budget_3_0-3.0.pdf
335876 RR_SubawardBudget30_3_0-3.0.pdf
335876 PHS398_ModularBudget_1_2-1.2.pdf
335876 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
335876 RR_SF424_2_0-2.0.pdf
335876 PHS398_CoverPageSupplement_5_0-5.0.pdf
335876 RR_OtherProjectInfo_1_4-1.4.pdf
335876 PerformanceSite_2_0-2.0.pdf
335876 RR_KeyPersonExpanded_2_0-2.0.pdf
335876 PHS398_ResearchPlan_4_0-4.0.pdf
335876 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
335876 RR_Budget_1_4-1.4.pdf
335876 RR_SubawardBudget30_1_4-1.4.pdf
335876 PHS398_ModularBudget_1_2-1.2.pdf
335876 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
335876 RR_SF424_5_0-5.0.pdf
335876 PHS398_CoverPageSupplement_5_0-5.0.pdf
335876 RR_OtherProjectInfo_1_4-1.4.pdf
335876 PerformanceSite_4_0-4.0.pdf
335876 RR_KeyPersonExpanded_4_0-4.0.pdf
335876 PHS398_ResearchPlan_5_0-5.0.pdf
335876 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335876 RR_Budget_3_0-3.0.pdf
335876 RR_SubawardBudget30_3_0-3.0.pdf
335876 PHS398_ModularBudget_1_2-1.2.pdf
335876 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
